This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

ImmunoGen, Inc. Announces Development Of Trastuzumab Emtansine For Early Stage HER2-Positive Breast Cancer

Stocks in this article: IMGN

ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced that Roche is implementing a “three-pronged approach” to developing trastuzumab emtansine (T-DM1) for early stage HER2-positive breast cancer, according to plans outlined by Roche at its 2012 ASCO analyst event. Trastuzumab emtansine uses ImmunoGen’s TAP technology with Roche’s trastuzumab antibody and is in global development by Roche under an agreement between ImmunoGen and Genentech, a member of the Roche Group.

In its analyst event presentation, Roche reported that it intends to initiate three studies with trastuzumab emtansine for early stage HER2-positive breast cancer, assessing the compound:

  • As single-agent therapy for patients with residual invasive disease following preoperative (neoadjuvant) systemic treatment;
  • Used in combination with chemotherapy and pertuzumab in the adjuvant setting; and
  • Used in combination with chemotherapy and pertuzumab in the neoadjuvant setting.

Roche expects to begin all three trials in 2013. Additional details on the plans reported are available on Roche’s website, www.roche.com.

“Genentech and Roche have unparalleled experience in the development of HER2-targeting antibody therapies for breast cancer,” commented Daniel Junius, President and CEO. “With the studies outlined today, their plans for trastuzumab emtansine now include registration studies across the spectrum of early stage to advanced HER2-positive breast cancer.”

Trastuzumab emtansine is currently being evaluated in three Phase III trials for the treatment of HER2-positive metastatic breast cancer. Data from the first of these, EMILIA, were reported in a plenary session at ASCO earlier today and, per Roche, will form the basis of its applying for marketing approval of the compound in the US and Europe.

Trastuzumab emtansine comprises ImmunoGen's DM1 cancer cell-killing agent linked using the Company’s method of attachment to the trastuzumab antibody developed by Genentech.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs